Screener
Jazz Pharmaceuticals JAZZ Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Jazz Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
FAQ
- What is Jazz Pharmaceuticals's debt-to-equity?
- Jazz Pharmaceuticals (JAZZ) reported debt-to-equity of 1.2× in Q1 2026.
- How has Jazz Pharmaceuticals's debt-to-equity changed year-over-year?
- Jazz Pharmaceuticals's debt-to-equity decreased by 8.0% year-over-year, from 1.3× to 1.2×.
- What is the long-term trend for Jazz Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's debt-to-equity has grown at a 15.4% compound annual growth rate (CAGR), from 0.6× to 1.3×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Jazz Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude